RSV prevention study for babies in Connecticut
Treatments studied
Part of Infections clinical trials.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is 12 months old or younger when they see a doctor for a respiratory illness.
- Your baby has a respiratory infection that started less than 10 days ago, with symptoms like fever, cough, or trouble breathing.
- Your baby lives in Connecticut.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody shot (called enflonsia) to help protect babies under 8 months old from RSV, a common virus that can cause breathing problems. If your baby qualifies, they will receive the shot and be followed for about 6 months to see how well it works.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study tests two approved ways to prevent RSV, a common virus that can make babies very sick. Pregnant women may get a vaccine, and/or their babies may get an antibody shot after birth. The study compares these options to see which works best.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.